Search

Serge R Martinod

from Groton, CT
Age ~69
Get Report
Also known as:
Serge R Marinod
Phone and address:
37 Skyline Dr, Groton, CT 06340
(860) 572-9698
Related to:
Kylie L Martinod, 32Kimberly Lindsay Martinod, 39
Connected to:
Amanda A Martinotti, 34Andrea A Martinos, 31Angela B Martino, 62Anita M Martino, 67Antoine Martino, 55Antonija Martinovic, 43Armando A Martino, 96Becky R Martinmaas, 68Bridget M Martino, 60Candace Martino, 31

Serge Martinod Phones & Addresses

  • 37 Skyline Dr, Groton, CT 06340 (860) 572-9698
  • Hollis, NY
  • Lincoln, NE
  • Boston, MA
  • Pawcatuck, CT
  • Mystic, CT
  • 37 Skyline Dr, Groton, CT 06340

Resumes

Resumes

Serge Martinod Photo 1

Serge Martinod

View page
Location:
New London, CT
Industry:
Veterinary
Education:
Ecole nationale vétérinaire de Lyon 1976 - 1980
Serge Martinod Photo 2

Chief Executive Officer

View page
Location:
New London, CT
Industry:
Alternative Medicine
Work:
TNG Pharmaceuticals - Louisville , KY since Nov 2012
CEO / CSO
Arcanatura since Jan 2008
Co-Founder
Education:
University of Nebraska at Omaha 1993 - 1995
Master of Business Administration (MBA) University of Science and Medicine Grenoble France 1980 - 1983
PhD, Biology, General School of Veterinary Medecine Lyon France 1976 - 1980
DVM, Veterinary Medicine
Skills:
Start Ups
Pharmaceutical Industry
Product Development
Drug Development
Strategic Planning
Lifesciences
Marketing Strategy
Biotechnology
Technology Transfer
Business Strategy
Entrepreneurship
Life Sciences
Drug Discovery
Clinical Development
R&D
New Business Development

Business Records

Name / Title
Company / Classification
Phones & Addresses
Serge Martinod
Partner, Principal
ARCANATURA, LLC
Business Services at Non-Commercial Site
37 Skyline Dr, Groton, CT 06340
Serge Martinod
PRES
CORONIS INC
7 Mason Is Rd, Mystic, CT 06355
Serge Martinod
DIRECTOR, Chief Executive Offi, Director
TNG PHARMACEUTICALS, INC
Livestock Services
201 E Jefferson St STE 201, Louisville, KY 40202
3722 Greenwich Rd, Louisville, KY 40218
37 Skyline Dr, Groton, CT 06340
Serge Martinod
Partner
M & S PARTNERSHIP LLC
37 Skyline Dr, Groton, CT 06340
Serge R. Martinod
Chairman
IG. TECH, INC
181 S Broad St #102, Pawcatuck, CT 06379
37 Skyline Dr, Groton, CT 06340
Serge Martinod
LACT, LLC
37 Skyline Dr, Groton, CT 06340
Serge Martinod
Principal
Zybel LLC
Business Services at Non-Commercial Site · Nonclassifiable Establishments
37 Skyline Dr, Groton, CT 06340

Publications

Us Patents

Sustained Release Delivery System

View page
US Patent:
8197839, Jun 12, 2012
Filed:
Jul 1, 2002
Appl. No.:
10/482335
Inventors:
Serge R. Martinod - Groton CT, US
Malcolm Brandon - Bulleen, AU
Assignee:
Virbac Corporation - Fort Worth TX
International Classification:
A61F 2/00
US Classification:
424426
Abstract:
A sustained release apparatus including at least one sustained release mini tablet implant; the or each mini tablet implant including a pharmaceutically active composition including at least one pharmaceutically active component; and a carrier therefor, wherein the or each tablet implant is of the coated tablet or covered rod type; the or each mini tablet implant being approximately 0. 1 to 0. 5 times the length and/or diameter of a single immediate release tablet capable of providing the desired threshold blood level depending on the pharmaceutical active selected, and having a payload of approximately 30% to 70% by weight of the total payload of an equivalent immediate release treatment conducted for an equivalent period; the sustained release apparatus providing, in use, zero order release of pharmaceutical active.

Preparation Of Sustained Release Pharmaceutical Composition

View page
US Patent:
20040234572, Nov 25, 2004
Filed:
Feb 26, 2004
Appl. No.:
10/487714
Inventors:
Serge Martinod - Groton CT, US
Malcolm Brandon - Bulleen, AU
Robert Packard - Wetherfield CT, US
International Classification:
A61F002/00
US Classification:
424/423000
Abstract:
A sustained release apparatus including a silicone support material; and a pharmaceutically active composition carried in or on the silicone support material; the pharmaceutically active composition including at least one pharmaceutically active component; and optionally a carrier therefor; the pharmaceutically active component being present in amounts of from approximately 30% to 75% by weight, based on the total weight of the sustained release apparatus.

Sustained Release Pharmaceutical Composition

View page
US Patent:
20040241204, Dec 2, 2004
Filed:
Jun 29, 2004
Appl. No.:
10/482336
Inventors:
Serge Martinod - Groton CT, US
Malcolm Brandon - Bulleen, AU
International Classification:
A61F002/00
US Classification:
424/426000
Abstract:
A sustained release apparatus including a plurality of sustained release mini-implants or pellets; each mini-implant including a sustained release support material; and a pharmaceutically active composition carried in or on the sustained release support material; the pharmaceutically active composition including at least one pharmaceutically active component; and a carrier therefor; each implant being of insufficient size and/or payload individually to provide a predetermined desired threshold blood level of pharmaceutical active for treatment of a selected indication.

Treatment Of Parasitic Disease

View page
US Patent:
20040247634, Dec 9, 2004
Filed:
Jun 29, 2004
Appl. No.:
10/482058
Inventors:
Serge Martinod - Groton CT, US
Malcolm Brandon - Bulleen, AU
International Classification:
A01N025/00
US Classification:
424/405000
Abstract:
The use of an anti-parasitic agent in a sustained form in the treatment of ectoparasitic infections.

Sustained Release Pharmaceutical Composition

View page
US Patent:
20050025806, Feb 3, 2005
Filed:
Jul 22, 2004
Appl. No.:
10/895957
Inventors:
Malcolm Brandon - Bulleen, AU
Serge Martinod - Groton CT, US
International Classification:
A61K048/00
A61K038/22
A61K038/19
A61K031/56
US Classification:
424423000, 514044000, 514012000, 514169000, 424085100
Abstract:
A sustained release delivery apparatus including a silicone support material formed from a methyl-vinyl siloxane polymer including a fumed silica as a reinforcing filler; a pharmaceutically active composition carried in or on the silicone support material; the pharmaceutically active composition including at least one growth and/or reproduction-associated pharmaceutical component; analogue thereof or derivative thereof; and a carrier therefor.

Radioopaque Sustained Release Pharmaceutical System

View page
US Patent:
20050063907, Mar 24, 2005
Filed:
Dec 9, 2002
Appl. No.:
10/495642
Inventors:
Malcolm Brandon - Bulleen Victoria, AU
Serge Martinod - Groton CT, US
International Classification:
A61K049/04
US Classification:
424009400
Abstract:
An at least partially radio-opaque sustained release delivery apparatus including a sustained release support material; a pharmaceutically active composition carried in or on the sustained release support material; and a material which renders the delivery apparatus at least partially radio-opaque; the pharmaceutically active composition including at least one pharmaceutically active component; and optionally carrier therefor; the pharmaceutically active component being present in amounts of from approximately 30% to 75% by weight, based on the total weight of the sustained release delivery apparatus; the radio-opaque material being carried in the support material, and/or in the pharmaceutically active composition.

Fusion Proteins Comprising Carriers That Can Induce A Dual Immune Response

View page
US Patent:
20050095258, May 5, 2005
Filed:
Nov 29, 2004
Appl. No.:
10/999363
Inventors:
Manuel Campos - Stonington CT, US
Terecita Yule - Norwich CT, US
Serge Martinod - Groton CT, US
Becky Durtschi - Ledyard CT, US
International Classification:
A61K039/00
C07H021/04
C12P021/04
C07K014/47
US Classification:
424192100, 435069700, 435320100, 435325000, 530350000, 536023500
Abstract:
The subject invention provides a fusion protein for producing a dual immune response in a vertebrate, which fusion protein comprises: (a) a first proteinaceous portion analogous to all or part of a peptide endogenously synthesized within the vertebrate, the activity of which peptide is to be inhibited within the vertebrate, and which proteinaceous portion by itself is incapable of eliciting an effective immunoinhibitory response in said vertebrate; connected to (b) a second proteinaceous portion analogous to all or part of an immunogen from a pathogen, which pathogen is capable of pathogenically infecting the vertebrate; the portion (b) causing the vertebrate's immune system to recognize the portion (a) and produce a response that: (i) inhibits the activity of the peptide endogenously synthesized within the vertebrate; and (ii) protects the vertebrate from infection by the pathogen, when the vertebrate is vaccinated with an effective amount of the fusion protein. The subject invention also provides fusion proteins which comprise a proteinaceous portion (b) that is a carrier that is analogous to all or part of a BHV-1 antigen, which fusion proteins induce in a vertebrate vaccinated with an effective amount of such fusion protein an immune response that inhibits the activity of a peptide as recited in (a), above.

Sustained Release Pharmaceutical Composition

View page
US Patent:
20050129728, Jun 16, 2005
Filed:
Sep 20, 2004
Appl. No.:
10/943947
Inventors:
Serge Martinod - Groton CT, US
Malcolm Brandon - Bulleen, AU
Robert Packard - Wetherfield CT, US
International Classification:
A61F002/00
US Classification:
424423000
Abstract:
A sustained release mini-implant including a silicone support material; and a pharmaceutically active composition carried in or on the silicone support rod; the pharmaceutically active composition including at least one pharmaceutically active component; and optionally a carrier therefor; the mini-implant providing a predetermined threshold blood level of pharmaceutical active for treatment of a selected indication.
Control profile
Serge R Martinod from Groton, CT, age ~69 Get Report